Arch Therapeutics Announces Formation of Medical Advisory Board to Advance Commercialization of AC5® Advanced Wound System
FRAMINGHAM, Mass., Jan. 18, 2023 (GLOBE NEWSWIRE) — Arch Therapeutics, Inc. (OTCQB:ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical products, today announced the formation of a medical advisory board (the “Medical Advisory Board”) comprised of respected wound care professionals across multiple medical specialties, including vascular surgery, podiatric medicine, and foot and ankle surgery. The Company believes that the Medical Advisory Board will support the strategic alignment of patient, payor, and provider goals to help advance the ongoing commercialization of its AC5® Advanced Wound System (“AC5”).
Related news for (ARTH)
- Arch Therapeutics to Present AC5® Advanced Wound System at the 2024 Symposium on Advanced Wound Care Spring Meeting (SAWC Spring)
- Arch Therapeutics Provides Year End Operational Update
- Arch Therapeutics to Present AC5® Advanced Wound System at the 2023 Symposium on Advanced Wound Care Fall Meeting (SAWC Fall)
- Arch Therapeutics Provides AC5® Commercialization Update
- Arch Therapeutics Completes Financing as Bridge to Uplisting